Chimeric Therapeutics Ltd begins collaboration with Sarah Cannon Research Institute for glioblastoma clinical trial

Chimeric Therapeutics Ltd (ASX:CHM), the only ASX clinical-stage cell therapy company, welcomes the participation of leading US centre Sarah Cannon Research...

Related Keywords

Texas ,United States ,American ,Jason Litten ,Chimeric Therapeutics Ltd ,Sarah Cannon Research Institute ,American Society Of Clinical Oncology ,Sarah Cannon Transplant ,Cellular Therapy Program ,South Austin Medical Center ,Chimeric Sponsored Phase ,American Society ,Clinical Oncology ,Central Nervous System Tumors ,